Please login to the form below
Indivior
Ashley Communications celebrates 20 years of medical communications
Among this number are big pharma firmsand Merck &Co, as well as UK-based Abbott Diagnostics, opioid addiction specialist Indivior, Tokyo-based Otsuka, detection and informatics specialist Perkin Elmer and Torax
Cogora buys PCM Healthcare to expand its med comms footprint
PCM delivers healthcare communications and non-promotional medical education to a range of clients, including Novartis, Gilead and Indivior.
Deal Watch table for November 2014
Vertex's CF portfolio. Royalty stream acquisition. 3, 300. Indivior / Reckitt Benckiser.
Pharma deals during November 2014
Reckitt Benckiser(RB) is spinning out its pharma business unit, under the name Indivior. ... Indivior will not be without its challenges as sales of its off-patent opioid addiction treatment Suboxone continue to slump.
Reckitt to spin-off pharma unit as Indivior
The RB Pharmaceuticals (RBP) unit will be spun-off with a separate UK listing as Indivior, which will be UK domiciled and traded on the London Stock Exchange's main market ... If the demerger - which has the full backing of Reckitt Benckiser's board –
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
CEO, Head of Health, UK
-
Six figure salary
-
Senior Account Manager
-
Competitive salary offered
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Valneva COVID-19 vaccine more effective than AZ
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- US demand for COVID-19 antibody treatments rising fast
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- AZ’s Imfinzi combination shows promise in liver cancer
- Call for industry innovators to join working group
- Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19
- US COVID-19 booster programme expanded
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- Towards Better HCP Engagement – An Email Masterclass
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Valneva COVID-19 vaccine more effective than AZ
- Innovation in a digital context is not about technology – it’s about people
- Beyond yoga and smoothies – providing real support for employee well-being
- The Future of eHealth: Contactless Health Monitoring
PMHub
certain health
Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
